Cervical Cancer Clinical Trials

Find Cervical Cancer Clinical Trials Near You

The Effect of Delivering HPV Education Through Different Methods on Young Women's Intention to Receive the Vaccine: A Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Detailed Description Human papillomavirus (HPV) is one of the leading causes of cervical cancer and can be prevented by vaccination. However, HPV vaccination rates among young women are low, largely due to insufficient knowledge and misconceptions about HPV and the vaccine. Therefore, an effective educational program may improve both knowledge and vaccination intention. The aim of this randomized controlled trial is to examine the effect of delivering HPV education through different methods (asynchronous online education delivered via a pre-recorded video and face-to-face education) on HPV knowledge level and HPV vaccination intention among women aged 18-24 years. The study will be conducted with women aged 18-24 years registered at Family Health Centers in the Afşin district of Kahramanmaraş, Türkiye. Eligible participants will be randomly assigned into three groups: the video-based education group, the face-to-face education group, and the control group. Data will be collected using the Participant Information Form, HPV Knowledge Scale, and HPV Vaccination Attitude and Intention Form. Measurements will be performed at three time points: before the education (pre-test), immediately after the education (post-test), and one month after the education (follow-up test). The video-based education group will receive the education via a pre-recorded online video, while the face-to-face group will receive the same content in person at the Family Health Center. No education will be provided to the control group; only measurements will be obtained. Research Questions Does HPV education delivered through different methods increase HPV knowledge levels among young women? Does HPV education increase HPV vaccination intention compared with the control group? Is face-to-face education more effective than video-based education in increasing vaccination intention? Are the improvements in knowledge and vaccination intention sustained one month after the education?

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 24
Healthy Volunteers: t
View:

• Participants must meet all of the following criteria to be included in the study:

• Aged 18-24 years,

• Residing in Afşin district, Kahramanmaraş province,

• Willing to voluntarily participate in the study,

• Literate and able to understand survey questions in Turkish,

• Have not previously received the HPV vaccine,

• Agree to be available throughout the study period (pre-test, post-education test, and 1-month follow-up test),

• Young women without physical or cognitive impairments or serious health problems that would prevent participation in the study.

Locations
Other Locations
Turkey
Afşin Aile Sağlığı Merkezleri
RECRUITING
Kahramanmaraş
Contact Information
Primary
Emel Asst. Prof.
emel_guclu4606@hotmail.com
03443004913
Time Frame
Start Date: 2025-12-15
Estimated Completion Date: 2026-03-31
Participants
Target number of participants: 117
Treatments
No_intervention: Control Group
Participants in this group will not receive any HPV education during the study period and will complete the same assessments as the intervention groups at all measurement time points.
Experimental: Video-Based Education Group
Participants in this group will receive HPV and HPV vaccination education delivered through a standardized educational video prepared in accordance with national health guidelines.
Experimental: Face-to-Face Education Group
Participants in this group will receive HPV and HPV vaccination education through face-to-face training provided by the researcher using standardized educational materials.
Sponsors
Leads: Emel GÜÇLÜ CİHAN
Collaborators: Kahramanmaras Sutcu Imam University

This content was sourced from clinicaltrials.gov